Predictors Of Local Control For Stereotactic Ablative Radiotherapy (Sabr) In Pulmonary Oligometastases From Gastrointestinal Malignancies

Background/Aim: To assess predictors of local control (LC) for stereotactic ablative radiotherapy (SAbR) in pulmonary oligometastatic disease (OMD) from gastrointestinal (GI) malignancies. Patients and Methods: Patients with pulmonary OMD treated with SAbR from January 2016 to December 2018 were included in this observational analysis. Primary endpoint was LC. Uni- and multivariate analyses to assess variable correlations were conducted. Results: Thirty-seven patients and 59 lung metastases were evaluated. The delivered dose was 30-60 Gy in 3-8 fractions. After a median follow-up of 23.0 months (range=6.3-50.4 months), LC rate at 1/2 years was 89.7%/85.0%, and increased to 96.0%/91.0% for lesions treated with a biologically effective dose (BED10) >= 100 Gy (p = 0.03). RECIST response at 6 months was predictive for LC (p = 0.002). Conclusion: SAbR is an effective option for pulmonary OMD from GI malignancies. A BED10 >= 100 Gy and radiological response at 6 months can affect LC.